1st Circuit Reverses Summary Judgment In Celexa/Lexapro Off-Label Suits

(January 31, 2019, 2:32 PM EST) -- BOSTON — The First Circuit U.S. Court of Appeals on Jan. 30 reversed summary judgment in an antidepressant off-label lawsuit but affirmed a trial court’s denial of class certification due to an expired statute of limitations (In Re:  Celexa and Lexapro Marketing and Sales Practices Litigation, Painters and Allied Trades District Council 82 Health Care Fund, et al. v. Forest Pharmaceuticals, Inc., et al., Nos. 18-1146 and 18-1147, 1st Cir., 2019 U.S. App. LEXIS 3079)....

Attached Documents

Related Sections